Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse
- 1 October 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 14 (10), 1413-1418
- https://doi.org/10.1002/ibd.20505
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: A prospective, uncontrolled, pilot studyClinical Gastroenterology and Hepatology, 2003
- Inflammatory Bowel DiseaseNew England Journal of Medicine, 2002
- Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: A multicenter studyJournal of Clinical Apheresis, 2001
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Serum Concentrations of Orosomucoid: Improved Decision-Making for Tapering Prednisolone Therapy in Patients with Active Inflammatory Bowel Disease?Scandinavian Journal of Gastroenterology, 1997
- Microalbuminuria in inflammatory bowel disease.Gut, 1994
- Intestinal permeability and the prediction of relapse in Crohn's diseaseThe Lancet, 1993
- Intestinal permeability in Crohnʼs disease and its relation to disease activity and relapse following treatment with an elemental dietEuropean Journal of Gastroenterology & Hepatology, 1993
- Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.Gut, 1988
- A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITYThe Lancet, 1980